- Investing Ideas
- /
- French Healthy high growth potential
French Healthy high growth potential
Results
8
Analysts expect these companies to experience strong growth in earnings over the next 3 years. They also meet criteria around being in an acceptable financial position.
8 companies
Innate Pharma
Market Cap: €145.6m
Operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
IPH
€1.58
7D
4.5%
1Y
-21.8%
VusionGroup
Market Cap: €4.2b
Engages in the provision of digitalization solutions for commerce in Europe, Asia, and North America.
VU
€250.80
7D
-1.1%
1Y
78.0%
Lhyfe
Market Cap: €159.9m
Produces and supplies renewable green hydrogen for mobility and industry markets.
LHYFE
€3.34
7D
-4.0%
1Y
-16.5%
Exail Technologies
Market Cap: €1.7b
Provides robotics, maritime, navigation, aerospace, and photonics technologies solutions in France and internationally.
EXA
€102.40
7D
8.2%
1Y
474.0%
MaaT Pharma
Market Cap: €71.3m
A late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival.
MAAT
€4.43
7D
-3.7%
1Y
-39.8%
Figeac Aero Société Anonyme
Market Cap: €466.1m
Manufactures, supplies, and sells equipment and sub-assemblers for aeronautics sector in France.
FGA
€11.00
7D
0.5%
1Y
94.3%
Eurazeo
Market Cap: €4.3b
A private equity and venture capital firm specializing in growth capital, series C, acquisitions, leveraged buyouts, and buy-ins of a private company, and investments in upper mid-market, mid-market and listed public companies, small- and mid-cap healthcare companies, equity in the small-mid and mid-large buyout segments.
RF
€62.85
7D
3.1%
1Y
-19.0%
Safran
Market Cap: €118.2b
Engages in the aerospace and defense businesses in France, rest of Europe, the Americas, the Asia-Pacific, Africa, and the Middle East.
SAF
€283.80
7D
2.8%
1Y
42.5%